EPAD Ambassador Craig Ritchie travels Down Under to disseminate EPAD’s rationale and gain Aussie support

On October 14th 2015, Craig Ritchie gave the Wicking Trust Public Lecture in Melbourne which is attended by various representatives of leading research bodies, policy think tanks, care providers, consumers and carers. One of his primary goals while there is to share information about EPAD and hopefully enlist support and involvement in the EPAD project…

EPAD team members meet Princess Anne in Scotland

On 15 October 2015, EPAD’s Luc Truyen, Vice-President, Neuroscience External Affairs, Janssen R&D (pictured here, with Princess Anne), along with the University of Edinburgh team, represented the EPAD consortium at a University event to launch the new offices for the Centre for Clinical Brain Sciences. They had the honour of introducing the project to Her…

European Prevention of Alzheimer’s Dementia Consortium (EPAD) Launches New Website

21 September 2015 –The European Prevention of Alzheimer’s Dementia Consortium (EPAD), a project co-funded by the Innovative Medicines Initiative (IMI) and the European Federation of Pharmaceutical Industries and Associations (EFPIA), announces today the official launch of www.ep-ad.org. The EPAD website is devoted to inform different audiences including the scientific community, companies, people with dementia, families…

EPAD ethics working group holds meeting

On 13 August 2015, EPAD’s ethics working group held an internal workshop in Amsterdam. Most of the meeting was taken up with discussions about issues to be covered in the EPAD ethical guidance document for clinicians and researchers involved in the project (in particular informed consent, disclosure of possible risk status and dealing with incidental…

35 partners from industry and academia to join European research initiative for the prevention of Alzheimer’s dementia

Paris, January 15, 2015 The members of the EPAD initiative today announced the start of a novel collaboration between academic and private sectors to test innovative treatments for the prevention of Alzheimer’s dementia.

Previous attempts to bring new drugs for Alzheimer’s disease to the market have been disappointing despite a high level of investment. However, the realisation that Alzheimer’s disease is a progressive disorder and that early intervention may be more effective has led to research efforts being focused on prevention. The goal of the initiative is the prevention of dementia in people with evidence of the disease (such as biomarker abnormalities as identified by specific tests), who still may have little or no complaints or clinical symptoms.

EPAD AGM and consortium meeting held in Edinburgh

The European Prevention of Alzheimer’s Dementia (EPAD) project held its consortium meeting in Edinburgh, Scotland on 19 to 21 May 2015. The title of the meeting, “Science, Collaboration and Progress” was very appropriate. There were many lively debates between leading researchers, clinicians, ethicists, lawyers and representatives of both pharmaceutical companies and people with dementia (Alzheimer…

EPAD project team holds meeting on dissemination activities

The members of EPAD’s communication team held a two day meeting in Barcelona on 9-10 April 2015. They discussed the ongoing development of the project communication plan and dissemination materials, such as the website, the internal and external newsletters and the project brochure. The partners also established dissemination procedures – including impact measures – for…